Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Profit After Tax: 2009-2024

Historic Profit After Tax for Northwest Biotherapeutics (NWBO) over the last 16 years, with Dec 2024 value amounting to -$83.8 million.

  • Northwest Biotherapeutics' Profit After Tax fell 38.48% to -$26.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$89.8 million, marking a year-over-year decrease of 29.11%. This contributed to the annual value of -$83.8 million for FY2024, which is 33.83% down from last year.
  • As of FY2024, Northwest Biotherapeutics' Profit After Tax stood at -$83.8 million, which was down 33.83% from -$62.6 million recorded in FY2023.
  • In the past 5 years, Northwest Biotherapeutics' Profit After Tax registered a high of $179.1 million during FY2021, and its lowest value of -$529.8 million during FY2020.
  • In the last 3 years, Northwest Biotherapeutics' Profit After Tax had a median value of -$83.8 million in 2024 and averaged -$83.8 million.
  • Per our database at Business Quant, Northwest Biotherapeutics' Profit After Tax plummeted by 2,445.75% in 2020 and then spiked by 133.81% in 2021.
  • Northwest Biotherapeutics' Profit After Tax (Yearly) stood at -$529.8 million in 2020, then skyrocketed by 133.81% to $179.1 million in 2021, then slumped by 158.64% to -$105.0 million in 2022, then skyrocketed by 40.40% to -$62.6 million in 2023, then tumbled by 33.83% to -$83.8 million in 2024.